Report cover image

Tinea Pedis - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18680161

Description

Tinea Pedis - Pipeline Insight, 2024



DelveInsight’s, Tinea Pedis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Tinea Pedis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Tinea Pedis Understanding

Tinea Pedis: Overview

Tinea pedis or foot ringworm is an infection of the feet affecting soles, interdigital clefts of toes, and nails with a dermatophyte fungus. It is also called athlete’s foot. The infection is caused by the dermatophyte, Trichophyton rubrum which was once endemic to many parts of Africa, Asia, and Australia. However, today the organism can be found in Europe and the Americas. Occlusion of toe clefts, maceration, and wet conditions with a simultaneous increase in the bacterial flora probably contribute to tinea pedis infection. Skin breakdown, humidity, and temperature play a role in this infection. The fungus released enzymes called keratinases to invade the keratin layer of skin. In addition, the dermatophyte cell wall also contains molecules called mannans which suppress the body's immune response.

""Tinea Pedis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tinea Pedis pipeline landscape is provided which includes the disease overview and Tinea Pedis treatment guidelines. The assessment part of the report embraces, in depth Tinea Pedis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tinea Pedis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Tinea Pedis R&D. The therapies under development are focused on novel approaches to treat/improve Tinea Pedis.
This segment of the Tinea Pedis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tinea Pedis Drugs
  • Dapaconazole: Biolab Sanus Farmaceutica
Dapaconazole is a inhibitor of 14 alpha demethylase, being developed by Biolab Sanus Farmaceutica, for the treatment of tinea pedis and tinea cruris.

Further product details are provided in the report……..

Tinea Pedis: Therapeutic Assessment

This segment of the report provides insights about the Tinea Pedis drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Tinea Pedis
There are approx. 5+ key companies which are developing the therapies for Tinea Pedis. The companies which have their Tinea Pedis drug candidates in the most advanced stage, i.e. Phase III include Biolab Sanus Farmaceutica.
  • Phases
DelveInsight’s report covers around 7+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Tinea Pedis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Intranasal
  • Intrathecal
  • Intravenous
  • Oral
  • Oral/Intravenous
  • Parenteral
  • Subcutaneous
  • Subcutaneous/Intramuscular
  • Transdermal
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Antisense oligonucleotide
  • Gene therapy
  • Hormones
  • Neuropeptides
  • Oligonucleotides
  • Small Molecule
  • Triglyceride
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tinea Pedis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tinea Pedis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tinea Pedis drugs.

Tinea Pedis Report Insights
  • Tinea Pedis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Tinea Pedis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Tinea Pedis drugs?
  • How many Tinea Pedis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tinea Pedis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tinea Pedis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Tinea Pedis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Sanotize Research and Development
  • DermBiont
  • Taro Pharmaceuticals USA
  • Blueberry Therapeutics
  • Biolab Sanus Farmaceutica
Key Products
  • Nitric oxide
  • DBI 002
  • TA 103
  • Terbinafine hydrochloride
  • DBI 001
  • Dapaconazole

Table of Contents

60 Pages
Introduction
Executive Summary
Tinea Pedis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Tinea Pedis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Dapaconazole: Biolab Sanus Farmaceutica
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DBI 002: DermBiont
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Terbinafine hydrochloride: Blueberry Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TA 103: Taro Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Tinea Pedis Key Companies
Tinea Pedis Key Products
Tinea Pedis- Unmet Needs
Tinea Pedis- Market Drivers and Barriers
Tinea Pedis- Future Perspectives and Conclusion
Tinea Pedis Analyst Views
Tinea Pedis Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us